Hyalex Orthopaedics appoints Adam Gridley to its Board of Directors and announces Dr. Tad Vail as Chief Medical Officer

– USA, MA –  Hyalex Orthopaedics, a privately held medical device company developing cartilage repair products based on the transformative HYALEX materials platform, announced the appointments of Adam Gridley to its Board of Directors, and of Dr. Tad Vail, (M.D.) as Chief Medical Officer

About Adam Gridley

Adam Gridley has over 25 years of experience in the biotechnology, medical device, and pharmaceutical industries leading venture capital-backed startups to fully integrated public commercial organizations. He is the CEO of Allay Therapeutics, a drug delivery biotechnology company, and previously was the CEO of Entera Bio, a biotechnology company specializing in the oral delivery of large molecules and biologics, as well as the CEO of Histogenics, a cell therapy and biologics company developing novel therapeutics for cartilage defects. At Histogenics, he led its IPO, multiple fundraising, and strategic transactions, and oversaw several successful clinical and manufacturing initiatives for the company’s Phase 3 trial of NeoCart. Before Histogenics, Mr. Gridley held several corporate and operational executive roles at Merz Pharma and BioForm Medical (including the sale to Merz), where he played a key role in an IPO as well as acquisitions and product launches. Mr. Gridley has served on the board of directors of LifeSprout and the Alliance for Regenerative Medicine (ARM) and is on the board of advisors for Life Science Cares Bay Area.

About Dr. Thomas Vail

Dr. Vail is internationally recognized as a specialist in total and partial joint replacement and surgical treatment of hip and knee conditions, having most recently served as the Michael and Antoinette Pappas endowed chair and James L. Young professor of orthopedic surgery at the University of California, San Francisco.

Prior to stepping down in 2023, Dr. Vail had served as chair of orthopedic surgery at UCSF since 2007, helping to establish the department as an international leader in patient care, research, education, and global health. His research focuses on the performance and outcomes of surgical procedures and devices, delivery of care in adult reconstruction, and cartilage repair strategies. He has published several hundred scientific articles, abstracts, book chapters, and educational materials on many facets of hip and knee surgery, surgical training and innovation, health economics, and patient care. He is the past president of the Knee Society, the American Association of Hip and Knee Surgeons, and the Eastern Orthopaedic Association, past vice president of the American Board of Orthopaedic Surgery, and currently sits on the board of trustees for the Journal of Bone and Joint Surgery. Additionally, Dr. Vail has multiple patents for orthopedic devices and has served as an industry consultant, participated on multiple scientific advisory boards, and helped to start companies in the musculoskeletal device space.

About Hyalex Orthopaedics

Hyalex is a privately held medical device company headquartered in Lexington, MA, developing transformational synthetic cartilage technology and implant systems for diseased and damaged joints. HYALEX Cartilage is protected by more than 17 patents and trademarks worldwide.

The HYALEX Cartilage platform has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration for a clinical trial in the United States. Hyalex is initiating first-in-human clinical studies of HYALEX Cartilage for knee cartilage repair in both the U.S. and Europe.

For more information: https://hyalex.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.